SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer

Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer

Joyce O’Shaughnessy, Cynthia Osborne, John Pippen et al. · New England Journal of Medicine · 2011 · 811 citations

Medicine, Oncology, Pharmacology +17

Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells

Anand G. Patel, Jann N. Sarkaria, Scott H. Kaufmann · Proceedings of the National Academy of Sciences · 2011 · 540 citations

Life Sciences, Genetics, Molecular Biology +17

Weekly Paclitaxel Improves Pathologic Complete Remission in Operable Breast Cancer When Compared With Paclitaxel Once Every 3 Weeks

Marjorie C. Green, Aman U. Buzdar, Terry Smith et al. · Journal of Clinical Oncology · 2005 · 421 citations

Medicine, Oncology, Pharmacology +15

Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer

Joyce O’Shaughnessy, Lee Schwartzberg, Michael A. Danso et al. · Journal of Clinical Oncology · 2014 · 305 citations · Full text

Medicine, Oncology, Pharmacology +15

Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase <i>In Vitro</i>

Anand G. Patel, Silvana B. De Lorenzo, Karen S. Flatten et al. · Clinical Cancer Research · 2012 · 211 citations · Full text

Medicine, Oncology, Pharmacology +13